Status note KOMODO-1 first-in-human trial (Part 2 dose expansion planned BBI-940 single agent or with fulvestrant). Terminated: the 10-Q states that preliminary exposure data from early KOMODO-1 dose-escalation cohorts, showing human oral bioavailability significantly lower than preclinical predictions, did not support continued clinical development. Company note: on June 22, 2026 Boundless Bio entered an Agreement and Plan of Merger with Serapha Bio (advancing SERP-01, an in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency), expected to close Q4 2026; future operations highly dependent on merger completion.
BBI-355
Phase 2 · TerminatedModality: oral small molecule inhibitor
Target CHK1
Indications
Oncogene-amplified cancers(Phase 2)
Status note Phase 1/2 POTENTIATE trial in oncogene-amplified cancers. May 2025: discontinued monotherapy arm and combination arms with third-party targeted therapies based on initial trial data. January 2026: ceased enrollment of the POTENTIATE trial entirely following strategic portfolio review (market considerations, clinical data, prioritization of BBI-940).
BBI-825
Stage not disclosed · TerminatedModality: oral small molecule inhibitor
Target ribonucleotide reductase (RNR)
Status note Ribonucleotide reductase (RNR) inhibitor designed to target ecDNA assembly and repair. Filing states a strategic decision not to proceed with evaluation in the planned first-in-human STARMAP Phase 1/2 trial; STARMAP winddown completed in 2025.
Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Institutional holders
Fund
Shares
Q/Q change
% of portfolio
Filing
ADAR1 Capital Management
1,968,216
+1,968,216
0.23%
2026-08-14
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.